Simon Powell

Simon Powell at Memorial Sloan Kettering Cancer Center studies DNA damage response in the context of both cancer therapy and synthetic lethality, particularly how defects in homologous recombination sensitize tumors to radiation plus PARP inhibitor combinations. His laboratory has elucidated the mechanistic interplay between BRCA genes, RAD51, and radiation-induced double-strand breaks. He has contributed to clinical trials combining radiotherapy with PARP inhibitors exploiting synthetic lethality in BRCA-deficient tumors. His work informs rational combination of DNA-damaging therapies with targeted agents.